| Names | |
|---|---|
| Preferred IUPAC name 4-(8-Methyl-2H,9H-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)aniline | |
| Identifiers | |
| |
3D model (JSmol) | |
| ChEBI | |
| ChEMBL | |
| ChemSpider |
|
| ECHA InfoCard | 100.162.378 |
| KEGG |
|
| UNII | |
| |
| |
| Properties | |
| C17H15N3O2 | |
| Molar mass | 293.326 g·mol−1 |
| Appearance | Yellow solid (HCl salt) |
| Density | 1.393 g/cm3 |
| >10 mg/mL (HCl salt) | |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
GYKI 52466 is a 2,3-benzodiazepine that acts as an ionotropicglutamatereceptor antagonist, which is a non-competitiveAMPA receptorantagonist (IC50 values are 10-20, ~ 450 and >> 50 μM for AMPA-, kainate- and NMDA-induced responses respectively), orally-activeanticonvulsant, andskeletal musclerelaxant.[1][2][3][4] Unlike conventional 1,4-benzodiazepines, GYKI 52466 and related 2,3-benzodiazepines do not act onGABAA receptors.[5] Like other AMPA receptor antagonists, GYKI 52466 has anticonvulsant andneuroprotective properties.[6]
CNS review:[7]